International practice of allergen products standardization

The article demonstrates that safe and efficacious use of allergen products for detection and treatment of allergic diseases relies on standardization and quality control methods. The article summarises various approaches to allergen products standardization that are used in the United States, the European Union and the Russian Federation. Development of requirements for allergen products of natural origin must take account of the heterogeneity of raw materials used in their production, since native allergen extracts are complex protein-polysaccharide mixtures consisting of allergenic (primary and secondary) and non-allergenic components. Standardization of methods used for evaluation of allergen products potency is performed using reference standards. To date, there exist several approaches to allergens standardization. The United States introduced a system of national reference standards whose biological activity is determined by one technique (IntraDermal Dilution for 50 mm sum of Erythema determines bioequivalent Allergy Units - ID₅₀EAL). In Europe each manufacturer establishes their own in-house reference standards (IHRS) and assigns them with units of activity. Products manufactured in the Russian Federation are standardized in protein nitrogen units (PNU).

аллергены, препараты аллергенов, главные аллергены, стандартизация, стандарты, биологическая активность, единицы активности, allergens, allergen products, major allergens, standardization, standards, biological activity, units of activity

1. Chruszcz M, Pomés A, Glesner J, Vailes LD, Osinski T, Porebski PJ, et al. Molecular determinants for antibody binding on group 1 house dust mite allergens. J Biol Chem. 2012; 287(10): 7388–98.

2. Thomas K, Bannon G, Herouet-Guicheney C, Ladics G, Lee L, Lee SI, et al. The utility of an international sera bank for use in evaluating the potential human allergenicity of novel proteins. Toxicol Sci. 2007; 97(1): 27–31.

3. Sundin B, Lilja G, Graff-Lonnevig V, Hedlin G, Heilborn H, Norrlind K, et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol. 1986; 77(3): 478–87.

4. Van Metre TE Jr, Marsh DG, Adkinson NF Jr, Kagey-Sobotka A, Khattignavong A, Norman PS Jr, Rosenberg GL. Immunotherapy for cat asthma. J Allergy Clin Immunol. 1988; 82(6): 1055–68.

5. Hedlin G, Graff-Lonnevig V, Heilborn H, Lilja G, Norrlind K, Pegelow K, et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol. 1991; 87(5): 955–64.

6. Hedlin G, Heilborn H, Lilja G, Norrlind K, Pegelow KO, Schou C, Løwenstein H. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol. 1995; 96(6 Pt 1): 879–85.

7. Wahn U, Schweter C, Lind P, Løwenstein H. Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies. J Allergy Clin Immunol. 1988; 82(3 Pt 1): 360–70.

8. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol. 1993; 91(3): 709–22.

9. Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson NF Jr, Buncher CR, et al. Ragweed immunotherapy in adult asthma. N Engl J Med. 1996; 334(8): 501–6.

10. Osterballe O. Immunotherapy in hay fever with two major allergens 19, 25 and partially purified extract of timothy grass pollen. A controlled double blind study. In vivo variables, season I. Allergy 1980; 35(6): 473–89.

11. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302(6771): 265–9.

12. Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999; 341(7): 468–75.

13. Fradkin VA. Diagnostic and therapeutic allergens. Moscow: Meditsina; 1990 (in Russian).

14. Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998; 81(5): 401–5.

15. Chapman MD, Ferreira F, Villalba M, Cromwell O, Bryan D, Becker WM, et al. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol. 2008; 122(5): 882–889.e2.

16. Filep S, Tsay A, Vailes L, Gadermaier G, Ferreira F, Matsui E, et al. A multi-allergen standard for the calibration of immunoassays: CREATE principles applied to eight purified allergens. Allergy 2012; 67(2): 235–41.

17. CRS catalogue. Available from: https://crs.edqm.eu.

18. Esch RE, Plunkett GA. Immunotherapy preparation guidelines, rules, and regulation. Curr Allergy Asthma Rep. 2013; 13(4): 406–13.

19. Yunginger JW. Allergens: recent advances. Pediatr Clin North Am. 1988; 35(5): 981–93.

20. Harden VA. A short history of the National Institutes of Health. Available from: http://history.nih.gov/exhibits/history/index.html.

21. Milestones in U. S. food and drug law history. U. S. Food and Drug Administration. Available from: http://www.fda.gov/opacom/backgrounders/miles.html.

22. Methods of the allergenic products testing laboratory. Bethesda. CBER (Docket No 94N-0012) Federal Register, 1994. Available from: https://goo.gl/nUmQcN.

23. Turkeltaub PC. Biological standardization of allergenic extracts. Allergol Immunopathol (Madr). 1989; 17(2): 53–65.

24. Turkeltaub PC, Rastogi SC, Baer H, Anderson MC, Norman PS. A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results. J Allergy Clin Immunol. 1982; 70(5): 343–52.

25. Guidance for Industry On the Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for an Allergenic Extract or Allergen Patch Test. Available from: https://goo.gl/epkiy9.

26. Guideline on allergen products: Allergen productsproduction and quality issues. Committee for medicinal products for human use (CHMP). (EMEA/CHMP/BWP/304831/2007) European Medicines Agency. London, 2008. Available from: https://goo.gl/ZrKMyV.

27. Allergen products. European Pharmacopoeia 9.0. Available from: http://online6.edqm.eu/ep900.

28. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. Committee for medicinal products for human use (CHMP) (CHMP/EWP/18504/2006). Available from: https://goo.gl/zWZEtJ.

29. Nordic Council on Medicines. Registration of Allergen Preparations: Nordic Guidelines, Volume 23. 1989.

30. Larenas-Linnemann D, Cox LS. European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol. 2008; 100(2): 137–45.

31. Major allergens strongly underrepresented in some immunotherapy against bee stings. Available from: https://goo.gl/ym1WMn.

32. Fernández-Caldas E, Zakzuk J, Lockey RF. Allergen Standardization and Characterization (September, 2009). Available from: https://goo.gl/9ggyXg.

33. Becker WM, Vogel L, Vieths S. Standardization of allergen extracts for immunotherapy: where do we stand? Curr Opin Allergy Clin Immunol. 2006; 6(6): 470–5.

34. Palomares O, Crameri R, Rhyner C. The contribution of biotechnology toward progress in diagnosis, management, and treatment of allergic diseases. Allergy 2014; 69(12): 1588–601.

35. Van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O, et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008; 63(3): 310–26.

36. Takai T, Okamoto Y, Okubo K, Nagata M, Sakaguchi M, Fukutomi Y, et al. Japanese Society of Allergology task force report on standardization of house dust mite allergen vaccines — secondary publication. Allergol Int. 2015; 64(2): 181–6.

37. Allergen nomenclature. WHO/IUIS Allergen Nomenclature Subcommittee. Available from: http://www.allergen.org/index.php.

38. Register branch standard samples of composition and properties of medical immunobiological preparations. The Ministry of health of the USSR. Issue 1. Moscow, 1988. P. 80 (in Russian).

39. Borisevich IV, Petukhov VG, Volkova RA, Ustinnikova OB, Fadeikina OV, Malkova VI. Standard samples as a tool to provide metrology of analytical methods of immunobiological medicines (IM) monitoring. BIOpreparations. Prevention, Diagnosis, Treatment 2010; 4(40): 8–10 (in Russian).